Announced in June 2025, the CNPV program aims to expedite the review of drugs that address unmet medical needs, improve affordability, or support public health priorities
Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied
Lipid peroxidations byproducts, such as 4-hydroxynonenal or malondialdehyde, can react with lysine amino groups, histidine imidazole groups, or cysteine sulphydryl groups to damage proteins (153)
Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
.png)
